Recent Updates
Recently added Catalysts
ACH Positive Sentiment

Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value

Monday, August 10, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Accendra Health, Inc. has adopted a Tax Asset Preservation Plan to safeguard long-term shareholder value. This plan aims to preserve the company's net operating loss carryforwards and other tax attributes, which is crucial for maintaining financial health. The Board of Directors believes this strategy will benefit shareholders in the long run.

Market Sentiment Analysis

POSITIVE FACTORS

  • Accendra Health aims to protect long-term shareholder value.
  • The adoption of a Tax Asset Preservation Plan is a proactive measure.
  • Preservation of net operating loss carryforwards can enhance financial stability.

Full Press Release Details

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) announced today that its Board of Directors adopted a Section 382 Rights Agreement (the “Tax Asset Preservation Plan”) designed to protect long-term shareholder value by facilitating the Company’s ability to preserve its net operating loss carryforwards (“NOLs”) and certain other tax attributes. A company generally experiences an ownership change if the percentage of the value of its stock owned by certain “5-percen

Frequently Asked Questions

What is the purpose of the Tax Asset Preservation Plan?

The plan aims to protect long-term shareholder value by preserving net operating loss carryforwards.

Who adopted the Tax Asset Preservation Plan?

The Board of Directors of Accendra Health adopted the plan.

What are net operating loss carryforwards?

NOLs are tax attributes that allow a company to offset future taxable income.

How does the plan benefit shareholders?

It enhances the company's ability to maintain financial stability and value.

ShareAdd on Google
Tags: ACH Viatris Investor Conferences Healthcare Accendra Health Tax Asset Preservation NOLs shareholder value
Last updated: Aug 10, 2026

Biotech snapshot

Cash runway
$337M liquidity · $17M/mo burn
~17 mo
Low dilution risk